Prevalence and Associated Factors of Hyperuricemia Among Cancer Patients Under Chemotherapy at Bugando Medical Centre in Mwanza.
Material type:
ABSTRACT:
Background: Cancer patients on chemotherapy mostly experience high serum levels (hyperuricemia) due to high destruction of cells, mostly dividing cells (DNA and RNA). Although chemotherapy is associated with hyperuricemia among cancer patients in relation to chemotherapy is still unclear at Bugando medical center (BMC). Mwanza. This study aims to determine the prevalence and associated factors of hyperuricemia among cancer patients under chemotherapy at BMC, Mwanza.
Methodology: Across sectional hospital based was conducted at BMC, Mwanza from May to July 2018 involved cancer patients on chemotherapy admitted or attended at BMC cancer unit with an estimated sample size of 217. Blood will be collected from consenting study participants and processed for detection of uric acid by using automated method (COBAS). Data was analyzed by using STATA version 13.0. Continuous data was presented as (+/-SD) or median while categorical data was presented as fractions or percentage. Chi-square was used to show the association between hyperuricemia and associated risk factors. P value of <0.05was considered as statistical significance.
Results: The majority of the participant; 110(51.6%) were females, the commonest cancer types, 70(32.9%) were the reproductive system. Of the 85(39.7%) cancer patients with hyperuricemia, the highest prevalence was seen in reproductive system cancer, 33/70(38.8%), followed by lymphatic system cancer, 20/16(23.5%) and exocrine system cancer, 15/35(17.7%). Hyperuricemia was common in males with significant association (p=0.001), also significantly associated with cancer types (p = 0.009, and chemotherapeutic agents given; Emeset (p =0.001), Casodex (p =0.005), Goserelin (p = <0.001), Paclitaxel (p =0.o43), Dexamethasone (p =0.009), Cyclophosphamide (p = 0.015) and Carboplatin (p = 0.044).
Conclusion: the prevalence of hyperuricemia among cancer patients under chemotherapy at BMC 1I 39.7%, more prevalently in males than female. Sex, cancer types and chemotherapy treatment have an association with hyperuricemia.
There are no comments on this title.